Respiratory Syncytial Virus News and Research

RSS

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.

23 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Potent nasal vaccine protects non-human primates from SARS-CoV-2

A team of US-based scientists has recently demonstrated the efficacy of a live attenuated, recombinant coronavirus disease 2019 (COVID-19) vaccine candidate currently under phase I clinical trial as a single-dose intranasal vaccine.

20 Jul 2021

Salivary markers of oxidative stress during severe COVID-19

An interesting study from researchers at the University of Sharjah, Sharjah, United Arab Emirates, presents evidence that an elevated level of expression of oxidant molecules may be correlated with severe infection and lung injury.

2 Jul 2021

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

A new preprint on the medRxiv* server adds fuel to this train of thought, showing that the required cell program is already active in children – namely, a higher expression of specific pattern recognition receptors (PRRs), which mediate an interferon (IFN) response.

30 Jun 2021

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A new study in the journal Nature Communications describes the process of converting a SARS-CoV-2 antibody into a multivalent form, thus enabling it to bind at various different points with its epitope.

21 Jun 2021

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

16 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

Researchers identify a bacterium with anti-SARS-CoV-2 activity in vitro: Dolosigranulum pigrum

As intensive efforts are on to counter the virus, a new study by an international team of researchers reports the unexpected success of a bacterium in modulating the immune response in the airway and protecting the cells against infection with this virus.

7 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

Could semen quality indicate SARS-CoV-2 insult susceptibility in polluted areas?

In a recent review in Environmental Science and Pollution Research, Italian researchers focused on “the evidence that correlates the degree and type of pollution with the increased susceptibility of many countries to this pandemic and proposes human semen as an early marker of the environmental health and the general health of individuals.” Their observations are based on a robust body of experimental evidence.

2 Jun 2021

Can immunity form and interaction with seasonal coronaviruses influence SARS-CoV-2 epidemiology?

A new study hypothesizes that cross-protection from seasonal epidemics of HCoVs could not only affect SARS-CoV-2 transmission but also protect children from the disease.

2 Jun 2021

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

According to research from the University of California, some cases of severe coronavirus disease 2019 (COVID-19) may be related to the immunological memory of previous H3N2 influenza A infection.

26 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

A new research paper published in the journal Science explores the differences in coronavirus-specific B memory cell repertoires in children versus adults, as well as the functional importance of this discovery.

18 May 2021

Total COVID-19 deaths could be 7 million

A new analysis from the Institute for Health Metrics and Evaluation (IHME), which independently researches health at the University of Washington School of Medicine, shows that the total global toll due to coronavirus disease 2019 (COVID-19) could be more than twice the officially reported number of deaths, at almost 7 million.

10 May 2021

Can control theory explain differences in virulence and transmission of SARS-CoV-2?

A new study discusses variations in viral pathogenicity and in transmission, which are responsible for asymptomatic infection and for superspreading events. The ability to understand this would open the way to understand how this virus behaves the way it does, in terms of its virulence, its spread, and its emergent variants of concern.

28 Apr 2021

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.

19 Apr 2021

Microbiota-derived molecules do not change the entry or replication of SARS-CoV-2 in intestinal cells

A study conducted at the University of Campinas in the state of São Paulo, Brazil, shows that compounds produced by gut microbiota (bacteria and other microorganisms) during fermentation of insoluble fiber from dietary plant matter do not affect the ability of the novel coronavirus SARS-CoV-2 to enter and replicate in cells lining the intestines.

30 Mar 2021

Respiratory Syncytial Virus News and Research

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Potent nasal vaccine protects non-human primates from SARS-CoV-2

Salivary markers of oxidative stress during severe COVID-19

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

Multivalent antibodies show high potency against SARS-CoV-2 in new study

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

Researchers identify a bacterium with anti-SARS-CoV-2 activity in vitro: Dolosigranulum pigrum

The great promise of antiviral peptides against SARS-CoV-2

Could semen quality indicate SARS-CoV-2 insult susceptibility in polluted areas?

Can immunity form and interaction with seasonal coronaviruses influence SARS-CoV-2 epidemiology?

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

Total COVID-19 deaths could be 7 million

Can control theory explain differences in virulence and transmission of SARS-CoV-2?

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

Microbiota-derived molecules do not change the entry or replication of SARS-CoV-2 in intestinal cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News